Aclaris Therapeutics (ACRS) Tops Q2 EPS by 3c, misses on revenue

Aclaris Therapeutics (NASDAQ: ACRS) reported Q2 EPS of ($0.42), $0.03 better than the analyst estimate of ($0.45). Revenue for the quarter came in at $1.87 million versus the consensus estimate of $1.9 million.

For earnings history and earnings-related data on Aclaris Therapeutics (ACRS) click here.

You May Also Be Interested In

• SanDisk upgraded at JPMorgan after investor day; shares climb
• Fox upgraded to overweight as Roku deal, ad strength lift outlook
• Boost Run, Inc. (BRUN) Reports Q2 Revenue of $31.1M